---
figid: PMC4075957__dhps-6-077Fig2
figlink: /pmc/articles/PMC4075957/figure/f2-dhps-6-077/
number: F2
caption: 'Paradoxical activation of the MAPK pathway.Notes: (A) Constitutively upregulated
  MAPK signaling by monomeric mutant BRAF (BRAFV600) is blocked by BRAF-specific inhibition
  using a selective BRAF inhibitor such as vemurafenib or dabrafenib. (B) In normal
  and tumor RAF wild-type cells, BRAF specific inhibition leads to paradoxic upregulation
  of the MAPK pathway. In these cells RAS activity is high, leading to RAF homodimerization
  or heterodimerization (eg, BRAF: BRAF, BRAF: CRAF, etc). BRAF-specific inhibition
  results in transactivation of the homodimeric or heterodimeric binding partner and
  increased downstream MAPK signaling.Abbreviations: ATP, adenosine triphosphate;
  MAPK, mitogen-activated protein kinase; RTK, receptor tyrosine kinases; Vem, vemurafenib;
  Dab, dabrafenib; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived
  growth factor receptor; IGF-1R, insulin-like growth factor 1 receptor; FGFR, fibroblast
  growth factor receptor.'
pmcid: PMC4075957
papertitle: New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib
  combination therapy.
reftext: Jason J Luke, et al. Drug Healthc Patient Saf. 2014;6:77-88.
pmc_ranked_result_index: '138197'
pathway_score: 0.9606419
filename: dhps-6-077Fig2.jpg
figtitle: 'Paradoxical activation of the MAPK pathway.Notes: (A) Constitutively upregulated
  MAPK signaling by monomeric mutant BRAF (BRAFV600) is blocked by BRAF-specific inhibition
  using a selective BRAF inhibitor such as vemurafenib or dabrafenib'
year: '2014'
organisms:
- Homo sapiens
ndex: d38f0741-debe-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4075957__dhps-6-077Fig2.html
  '@type': Dataset
  description: 'Paradoxical activation of the MAPK pathway.Notes: (A) Constitutively
    upregulated MAPK signaling by monomeric mutant BRAF (BRAFV600) is blocked by BRAF-specific
    inhibition using a selective BRAF inhibitor such as vemurafenib or dabrafenib.
    (B) In normal and tumor RAF wild-type cells, BRAF specific inhibition leads to
    paradoxic upregulation of the MAPK pathway. In these cells RAS activity is high,
    leading to RAF homodimerization or heterodimerization (eg, BRAF: BRAF, BRAF: CRAF,
    etc). BRAF-specific inhibition results in transactivation of the homodimeric or
    heterodimeric binding partner and increased downstream MAPK signaling.Abbreviations:
    ATP, adenosine triphosphate; MAPK, mitogen-activated protein kinase; RTK, receptor
    tyrosine kinases; Vem, vemurafenib; Dab, dabrafenib; EGFR, epidermal growth factor
    receptor; PDGFR, platelet-derived growth factor receptor; IGF-1R, insulin-like
    growth factor 1 receptor; FGFR, fibroblast growth factor receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK1
  - FGFR2
  - MAPK3
  - ARAF
  - PDGFRB
  - EGFR
  - PDGFRA
  - FGFR4
  - RAF1
  - FGFR1
  - FGFR3
  - BRAF
  - IGF1R
  - MAP2K1
  - MAP2K2
  - FGFRL1
  - HRAS
  - NRAS
  - KRAS
  - tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: FGFR,
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PDGFR,
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: EGFR,
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PDGFR,
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: FGFR,
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: FGFR,
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR,
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: IGF-1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: FGFR,
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals:
- word: tyrosine
  source: MESH
  identifier: D014443
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4075957__F2
redirect_from: /figures/PMC4075957__F2
figtype: Figure
---
